28 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement Study

Sponsor
DePuy Orthopaedics (Industry)
Overall Status
Completed
CT.gov ID
NCT00208507
Collaborator
(none)
264
2
2
92
132
1.4

Study Details

Study Description

Brief Summary

The study is designed to evaluate artificial hips with a 28 mm ceramic head and a ceramic liner to determine whether they perform as well as artificial hips with a 28 mm ceramic head and a polyethylene liner.

Condition or Disease Intervention/Treatment Phase
  • Device: 28 mm ceramic head on ceramic acetabular liner.
  • Device: 28 mm ceramic head on polyethylene liner
N/A

Detailed Description

Total Hip Arthroplasty (THA) is the surgical reconstruction of the hip joint through replacement of the femoral head and the acetabular articulating surfaces with fixed prosthetic devices. The goals of THA are relief from pain, restoration of function, and correction of deformity. THA is one of the most common adult reconstructive procedures. Over the past 25 years, patients who have needed to have their hip joint replaced, either due to trauma or arthritic disease, typically have had their hip joint bone articular surfaces replaced with a metal hip stem, metal ball head (either stainless steel or chrome cobalt) and a plastic acetabular cup (metal/metal/plastic). While the basic device has remained essentially unchanged over that period, technological advancements in implant designs and materials, and improvements in surgical technique and instrumentation have made THA one of the most durable and successful procedures in medicine. Reproducible, high-quality, short-term and mid-term results are attained regularly, and total hip replacements commonly last 10 to 15 years and longer. The success of this procedure has allowed its expansion into a wider, and often younger and more active population.

In spite of the improvements in THA, little change has occurred for the acetabular cup liner, which is usually made out of Ultra High Molecular Weight Polyethylene plastic (UHMWPe). Because it is plastic and inherently soft and somewhat pliable under load, the cup's articular surface must inevitability wear and produce debris. This biologic response is now thought to be a significant contributor to prosthetic component loosening, a primary failure mode of THR. UHMWPe also degrades with time in the body. As concerns about polyethylene wear and the associated untoward effects of the generated wear debris, and as THA continues to be used in younger and higher-demand patients with increasing life expectancies, interest in ceramic on ceramic total hip prosthesis has been renewed.

An alumina ceramic-on-ceramic acetabular coupling has been employed as an alternative to metal/polyethylene couplings. This ceramic-on-ceramic coupling has many advantages, including the elimination of polyethylene from the device system, wear rates that are appreciably less than those experienced with metal/polyethylene couplings and reduced biologic reactivity. The potential benefits of an alumina ceramic/ceramic bearing are significant.

Study Design

Study Type:
Interventional
Actual Enrollment :
264 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prosthesis Study (28mm)
Study Start Date :
Apr 1, 2003
Actual Primary Completion Date :
Mar 1, 2008
Actual Study Completion Date :
Dec 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Delta Ceramax Ceramic-on-Ceramic Acetabular Cup System

Total hip replacement with a 28 mm ceramic head and liner.

Device: 28 mm ceramic head on ceramic acetabular liner.
Total hip replacement with 28 mm ceramic head on ceramic liner articulation
Other Names:
  • Delta Ceramax™ 28 mm Ceramic-on-Ceramic Acetabular Cup
  • Active Comparator: Pinnacle™ Acetabular Cup with Marathon® Polyethylene

    Total hip replacement with 28 mm ceramic head with a polyethylene liner.

    Device: 28 mm ceramic head on polyethylene liner
    Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
    Other Names:
  • Detla Ceramax 28 mm ceramic femoral head and Marathon polyethylene liner.
  • Outcome Measures

    Primary Outcome Measures

    1. Harris Hip Total Score [6 weeks, 6, 12 months and last follow up at 24 months or greater]

      The Harris Hip scoring system assigns a numeric value to responses from patients and assessments made by a surgeon. A score of 91-100 is excellent, 81-90 is good, 71-80 is fair, 70 or below is poor. The patient records the following: pain level, need for assistance when walking, presence of a limp, distance able to walk, ability to put on shoes and socks, climb stairs, use public transportation and the length of time one is able to comfortably sit in a chair are all scored.

    Secondary Outcome Measures

    1. Complication Rates [On-going to end of study]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Non-inflammatory degenerative joint disease. Composite diagnoses of NIDJD include osteoarthritis, avascular necrosis, post-traumatic arthritis, slipped capital femoral epiphysis (SCFE), fracture of the pelvis, and developmental dysplasia.

    • X-ray evaluation confirms the presence of NIDJD

    • Femoral and acetabular bone stock is sufficient, regarding strength and shape, and is suitable to receive the implants.

    • Individuals 20 to 75 years of age at the time of surgery

    • Patients with a previous total hip replacement of the contralateral leg who have a pain rating of none or slight and who are at least one year post arthroplasty are eligible for participation in the study.

    • Harris Hip Score of 70 or lower

    • Pain at least Moderate

    Exclusion Criteria:
    • Presence of a previous prosthetic hip replacement device (any type, including surface replacement arthroplasty, endoprosthesis, etc.) in the hip joint to be operated.

    • Previous Girdlestone procedure (resection arthroplasty) or surgical fusion of the hip to be operated.

    • Acute femoral neck fracture.

    • Above knee amputation of the contralateral and/or ipsilateral leg.

    • Patients with bilateral degenerative joint disease requiring staged or simultaneous hip replacements.

    • Patients with an existing total hip arthroplasty in the contralateral hip with a Harris Hip pain rating of mild, moderate, marked or totally disabled.

    • Patients who have undergone total hip arthroplasties in their contralateral hips within the past 12 months.

    • Patients with a known allergy to metal (e.g. jewelry).

    • Skeletally immature patients (tibial and femoral epiphyses are not closed). Evidence of active infections that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of the hip joint, overt infection, urinary tract infection, etc.).

    • The presence of highly communicable disease or diseases that may limit follow-up (e.g., immuno-compromised conditions, hepatitis, active tuberculosis, etc.).

    • Presence of known metastatic or neoplastic disease.

    • Significant neurologic or musculoskeletal disorders or disease that may adversely affect gait or weight bearing, (e.g., muscular dystrophy, multiple sclerosis).

    • Conditions that may interfere with the total hip arthroplasty's survival or outcome, (e.g., Paget's disease, Charcot's disease).

    • Any patient believed to be unwilling or unable to comply with a rehabilitation program for a cementless total hip replacement or who indicates difficulty or inability to return for follow-up visits prescribed by the study protocol.

    • Patient is known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser.

    • Any systemic steroid therapy, excluding inhalers, within three months prior to surgery.

    • Patients carrying the diagnosis of inflammatory degenerative arthritis (IDJD) to include the following composite diagnoses: rheumatoid arthritis, systemic lupus erythematosus, pigmented villonodular synovitis, juvenile rheumatory arthritis and other arthritic processes of inflammatory or autoimmune etiology.

    • Patients requiring structural bone grafts in order to support the prosthetic component(s) or to shape the bone to receive the implant(s).

    • Patients who refuse to provide consent to participate in the clinical investigation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Colorado Joint Replacement Denver Colorado United States 80210
    2 Cardinal Orthopaedic Institute Columbus Ohio United States 43213

    Sponsors and Collaborators

    • DePuy Orthopaedics

    Investigators

    • Principal Investigator: Joel Politi, MD, Cardinal Orthopaedic Institute
    • Principal Investigator: Douglas Dennis, MD, Colorado Joint Replacement

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    DePuy Orthopaedics
    ClinicalTrials.gov Identifier:
    NCT00208507
    Other Study ID Numbers:
    • COC 28 mm
    First Posted:
    Sep 21, 2005
    Last Update Posted:
    Jan 24, 2014
    Last Verified:
    Dec 1, 2013
    Keywords provided by DePuy Orthopaedics
    Additional relevant MeSH terms:

    Study Results

    Participant Flow

    Recruitment Details Patients were selected for recruitment into the study from the general diagnosis population defined as "primary total hip arthroplasty (THA) for non-inflammatory degenerative joint disease (NIDJD)." The investigation was conducted at 8 centers. Each center randomly assigned patients to both the investigational and control treatment groups.
    Pre-assignment Detail
    Arm/Group Title Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup System Pinnacle™ Acetabular Cup With Marathon® Polyethylene
    Arm/Group Description The Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prosthesis System consists of a modular ceramic bearing insert that attaches to a Pinnacle™ Acetabular Shell by a taper locking mechanism. The ceramic insert is designed to articulate against a 28 mm ceramic femoral head that is attached to a conventional femoral stem to complete the total hip prosthesis. Pinnacle™ acetabular shells are a hemispherical type of acetabulum replacement prosthesis that incorporates Porocoat® porous coating for biologic fixation to host bone. The 28mm ceramic femoral heads were used with Marathon® polyethylene liners. The polyethylene insert is designed to articulate against a 28 mm ceramic femoral head that is attached to a conventional femoral stem to complete the total hip prosthesis.
    Period Title: Overall Study
    STARTED 177 87
    COMPLETED 163 79
    NOT COMPLETED 14 8

    Baseline Characteristics

    Arm/Group Title Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup System Pinnacle™ Acetabular Cup With Marathon® Polyethylene Total
    Arm/Group Description The Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prosthesis System consists of a modular ceramic bearing insert that attaches to a Pinnacle™ Acetabular Shell by a taper locking mechanism. The ceramic insert is designed to articulate against a 28 mm ceramic femoral head that is attached to a conventional femoral stem to complete the total hip prosthesis. Pinnacle™ acetabular shells are a hemispherical type of acetabulum replacement prosthesis that incorporates Porocoat® porous coating for biologic fixation to host bone. The 28mm ceramic femoral heads were used with Marathon® polyethylene liners. The polyethylene insert is designed to articulate against a 28 mm ceramic femoral head that is attached to a conventional femoral stem to complete the total hip prosthesis. Total of all reporting groups
    Overall Participants 177 87 264
    Age (years) [Mean (Standard Deviation) ]
    Mean (Standard Deviation) [years]
    56.4
    (10.6)
    57.3
    (10.3)
    56.7
    (10.5)
    Sex: Female, Male (Count of Participants)
    Female
    87
    49.2%
    40
    46%
    127
    48.1%
    Male
    90
    50.8%
    47
    54%
    137
    51.9%
    Region of Enrollment (participants) [Number]
    United States
    177
    100%
    87
    100%
    264
    100%

    Outcome Measures

    1. Primary Outcome
    Title Harris Hip Total Score
    Description The Harris Hip scoring system assigns a numeric value to responses from patients and assessments made by a surgeon. A score of 91-100 is excellent, 81-90 is good, 71-80 is fair, 70 or below is poor. The patient records the following: pain level, need for assistance when walking, presence of a limp, distance able to walk, ability to put on shoes and socks, climb stairs, use public transportation and the length of time one is able to comfortably sit in a chair are all scored.
    Time Frame 6 weeks, 6, 12 months and last follow up at 24 months or greater

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup System Pinnacle™ Acetabular Cup With Marathon® Polyethylene
    Arm/Group Description The Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prosthesis System consists of a modular ceramic bearing insert that attaches to a Pinnacle™ Acetabular Shell by a taper locking mechanism. The ceramic insert is designed to articulate against a 28 mm ceramic femoral head that is attached to a conventional femoral stem to complete the total hip prosthesis. Pinnacle™ acetabular shells are a hemispherical type of acetabulum replacement prosthesis that incorporates Porocoat® porous coating for biologic fixation to host bone. The 28mm ceramic femoral heads were used with Marathon® polyethylene liners. The polyethylene insert is designed to articulate against a 28 mm ceramic femoral head that is attached to a conventional femoral stem to complete the total hip prosthesis.
    Measure Participants 177 87
    Pre-operative
    50.5
    (9.6)
    50.8
    (9.5)
    6 weeks
    75.7
    (12.3)
    73.6
    (12.7)
    6 months
    92.2
    (11.4)
    91.4
    (11.6)
    12 months
    94.2
    (10.1)
    93.7
    (9.6)
    last follow up of 24 months or greater
    94.6
    (9.3)
    94.5
    (8.0)
    Statistical Analysis 1
    Statistical Analysis Overview Comparison Group Selection Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup System, Pinnacle™ Acetabular Cup With Marathon® Polyethylene
    Comments
    Type of Statistical Test Non-Inferiority or Equivalence
    Comments This was a non-inferiority test of the Harris Hip Score means at 24+ months with a 5 point non-inferiority margin.
    Statistical Test of Hypothesis p-Value 0.001
    Comments
    Method ANCOVA
    Comments Preoperative Harris Hip score was included in the ANCOVA model as the only covariate.
    Method of Estimation Estimation Parameter Mean Difference (Final Values)
    Estimated Value 0.61
    Confidence Interval (1-Sided) 95%
    -1.56 to
    Parameter Dispersion Type:
    Value:
    Estimation Comments
    2. Secondary Outcome
    Title Complication Rates
    Description
    Time Frame On-going to end of study

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title
    Arm/Group Description

    Adverse Events

    Time Frame
    Adverse Event Reporting Description
    Arm/Group Title Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup System Pinnacle™ Acetabular Cup With Marathon® Polyethylene
    Arm/Group Description The Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prosthesis System consists of a modular ceramic bearing insert that attaches to a Pinnacle™ Acetabular Shell by a taper locking mechanism. The ceramic insert is designed to articulate against a 28 mm ceramic femoral head that is attached to a conventional femoral stem to complete the total hip prosthesis. Pinnacle™ acetabular shells are a hemispherical type of acetabulum replacement prosthesis that incorporates Porocoat® porous coating for biologic fixation to host bone. The 28mm ceramic femoral heads were used with Marathon® polyethylene liners. The polyethylene insert is designed to articulate against a 28 mm ceramic femoral head that is attached to a conventional femoral stem to complete the total hip prosthesis.
    All Cause Mortality
    Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup System Pinnacle™ Acetabular Cup With Marathon® Polyethylene
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total / (NaN) / (NaN)
    Serious Adverse Events
    Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup System Pinnacle™ Acetabular Cup With Marathon® Polyethylene
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 27/177 (15.3%) 14/87 (16.1%)
    Cardiac disorders
    Cardiovascular 1/177 (0.6%) 1 0/87 (0%) 0
    Endocrine disorders
    Endocrine/Metabolic 1/177 (0.6%) 1 2/87 (2.3%) 2
    Gastrointestinal disorders
    Gastrointestinal 2/177 (1.1%) 2 2/87 (2.3%) 2
    Injury, poisoning and procedural complications
    Dislocation 0/177 (0%) 0 1/87 (1.1%) 1
    Musculoskeletal and connective tissue disorders
    Musculoskeletal 16/177 (9%) 16 8/87 (9.2%) 8
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Cancer 3/177 (1.7%) 3 2/87 (2.3%) 2
    Nervous system disorders
    Neurological 1/177 (0.6%) 1 0/87 (0%) 0
    Renal and urinary disorders
    Genitourinary 1/177 (0.6%) 1 0/87 (0%) 0
    Respiratory, thoracic and mediastinal disorders
    Respiratory 1/177 (0.6%) 1 0/87 (0%) 0
    Surgical and medical procedures
    Acetabular liner failure 1/177 (0.6%) 1 0/87 (0%) 0
    Femoral Component Loosening 1/177 (0.6%) 1 0/87 (0%) 0
    Other (Not Including Serious) Adverse Events
    Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup System Pinnacle™ Acetabular Cup With Marathon® Polyethylene
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 80/177 (45.2%) 44/87 (50.6%)
    Cardiac disorders
    Cardiovascular 11/177 (6.2%) 11 6/87 (6.9%) 6
    Injury, poisoning and procedural complications
    Wound Problem 9/177 (5.1%) 9 2/87 (2.3%) 2
    Musculoskeletal and connective tissue disorders
    Musculoskeletal 68/177 (38.4%) 68 36/87 (41.4%) 36
    Renal and urinary disorders
    Genitourinary 10/177 (5.6%) 10 7/87 (8%) 7

    Limitations/Caveats

    [Not Specified]

    More Information

    Certain Agreements

    Principal Investigators are NOT employed by the organization sponsoring the study.

    The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.

    Results Point of Contact

    Name/Title Dave Whalen
    Organization DePuy Orthopaedics, Inc
    Phone 574-372-7028
    Email DWhalen@its.jnj.com
    Responsible Party:
    DePuy Orthopaedics
    ClinicalTrials.gov Identifier:
    NCT00208507
    Other Study ID Numbers:
    • COC 28 mm
    First Posted:
    Sep 21, 2005
    Last Update Posted:
    Jan 24, 2014
    Last Verified:
    Dec 1, 2013